Effect of Xiaoshuan Enteric-coated Capsule on Platelet Activating Factor in Hypertension Patients with Cardiovascular Risk Factors

邱晓敏,张继平,彭健,姚晖,郑菊芬
DOI: https://doi.org/10.13457/j.cnki.jncm.2012.02.076
2012-01-01
Abstract:Objective:To investigate the effect of Xiaoshuan enteric-coated capsules(XSECC) on platelet activating factor(PAF) activity in hypertension patients with cardiovascular risk factors.Methods:Sixty hypertension patients were randomly divided into XSECC group(n=30) and aspirin group(n=30),and thirty healthy volunteers served as healthy control group.Serum PAF content was detected before and after treatment.Results:PAF content was(28.05±7.40)ng/mL and(27.51±7.61)ng/mL before treatment,and was(8.67±3.93)ng/mL and(11.36±3.03)ng/mL after treatment in XSECC group and Aspirin group.After treatment,PAF content of XSECC group was obviously lower than that of aspirin group(P < 0.01).Conclusion:The clinical antithrombotic therapy can significantly reduce PAF content of hypertension patients with cardiovascular risk factors,while the decrease of XSECC group is more obvious,indicating that XSECC is able to reduce serum PAF content through multiple ways and by multiple targets.
What problem does this paper attempt to address?